The Medicines Company Reports Third-Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Medicines Co. (MDCO) Reports Q3 Loss of $0.70
November 8, 2018 7:15 AM ESTMedicines Co. (NASDAQ: MDCO) reported Q3 EPS of ($0.70).
During the third quarter of 2018, we continued to advance inclisiran through Phase III trials and other, key development steps, said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. We... More
